Skip to main content
Premium Trial:

Request an Annual Quote

Skuldtech Changes Name to Acobiom to Signal Focus on Personalized Medicine


NEW YORK (GenomeWeb) -- French firm Skuldtech announced that it has changed its name to Acobiom.

Skuldtech, founded in 1999, historically has focused on genomic and transcriptomic biomarker discovery and diagnostic development. The name change signifies that the company is strategically shifting its focus toward personalized medicine.

"In taking the name Acobiom, the company seeks to promote and develop its companion diagnostics and its expertise in the discovery of new biomarkers," the firm said in a statement. "It also embodies their strong position within ‘omics’ technologies."

As Acobiom, the firm said it intends to launch new companion tests on the market in coming months, as well as launch oncology trials. The company has filed two cancer related patents related to its tests and is planning to file two more by year end. Additionally, it is planning to expand its services offerings around ‘omics’ technologies, sequencing, and bioinformatics.

Since 1999, Acobiom has raised a total of EUR 1.5 million ($2.04 million) from private investors. Additionally, Acobiom has received EUR 1.3 million from Bpifranc, a French public investment bank, for two projects with a pharmaceutical partner on pancreatic cancer and Alzheimer's disease.

"Acobiom is now seeking additional funding to finance its clinical trials," the company said in a statement. Long term, the company may consider a public offering in order to finance the marketing of its first companion diagnostics.

Filed under